2017
Immunotherapy in Lung Cancer
Du L, Herbst RS, Morgensztern D. Immunotherapy in Lung Cancer. Hematology/Oncology Clinics Of North America 2017, 31: 131-141. PMID: 27912829, DOI: 10.1016/j.hoc.2016.08.004.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerAdvanced stage non-small cell lung cancerPD-1/PD-L1 axisFirst-line platinum-based doubletStage non-small cell lung cancerApproval of nivolumabPlatinum-based doubletsSecond-line docetaxelGood performance statusImmune checkpoint inhibitorsPD-L1 axisMinority of patientsRandomized clinical trialsTreatment of patientsNew therapeutic approachesClass of drugsCheckpoint inhibitorsOverall survivalPerformance statusClinical trialsProlonged benefitTherapeutic approachesPatients
2008
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
Giaccone G, Iacona RB, Fandi A, Janas M, Ochs JS, Herbst RS, Johnson DH. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. Journal Of Cancer Research And Clinical Oncology 2008, 135: 467-476. PMID: 18787840, DOI: 10.1007/s00432-008-0466-3.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiopsyCarcinoma, Non-Small-Cell LungCell DivisionErbB ReceptorsGefitinibGene Expression Regulation, NeoplasticHumansImmunohistochemistryLung NeoplasmsNeoplasm StagingPlacebosPlatinum CompoundsPrognosisQuinazolinesSurvival AnalysisConceptsPlatinum-based chemotherapyCell lung cancerPrognostic factorsLung cancerFirst-line platinum-based chemotherapyEpidermal growth factor receptor stainingChemotherapy-naive patientsPlacebo-controlled trialCox regression analysisReceptor expression analysisStrong prognostic indicatorMembrane stainingEGFR expression correlatesSurvival benefitImproved survivalPrognostic effectGrowth patternPredictive factorsPrognostic indicatorReceptor stainingPoor survivalTreatment groupsEGFR PharmDxEGFR expressionGefitinib